Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
When will we hear, Is there a certain date we should hear by?
I recall someone suggested the 28th, was the time frame for guidance only or are there set deadlines to release the information on the CTA application?
TIA
What the doom mongers always over look is that in mid 2020 the SP was 19p in todays price that’s an 850% rise thus far. If we had reverted back to somewhere near 19p they might of had a point. It does make you think what their motives are. DYOR, GLA
As the lead developer, Sareum is likely to receive a much higher proportion of any licensing deal it secures for its TYK2/JAK1 inhibitors. The Company continues to actively engage with potential partners with a view to securing commercial licences for this programme. Optimising the time to strike a deal is a delicate balance of funding and risk management. The further Sareum takes its programme the higher the potential rewards, but also the higher the risk of clinical failure. This is mitigated to some extent by Sareum having two molecules in development. The completion of SDC-1801’s pre-clinical work in the coming months is the next milestone to look out for. A solid pre-clinical package will give Sareum optionality. It does not have to divest all of the crown jewels now particularly if a deal is not front end loaded. Having a second candidate also gives Sareum room for flexibility.
However, should Sareum successfully take one or both candidates into, or to the end of Phase 1, the returns promise to generate a significant multiple of the current market capitalisation of £60.5m as at the close of business on 2 February. The programme has the potential to generate one or more blockbusters, and positive news flow from the Covid-19 project will do no harm in focussing partner and investor attention on these exciting molecules.
https://www.google.co.uk/amp/s/masterinvestor.co.uk/equities/stocks-in-focus-sareum-holdings/amp/
Gropelad: Got to agree it has been spouted for years, I remember it being said when the SP was .025 old money. If only you had listened then you would have multi bagged time and time again all the way up to 9p. But you know best
When this was published and mentioned in the RNS
https://www.jimmunol.org/content/193/7/3278
Not too sure if up to date but took this from the below report that I belt is dated this year, forgive me if I have got this wrong.
“ Another oral CHK1 inhibitor,SRA737, when combined with low dose gemcitabine,enhances the effect of anti-PD-L1 in a small cell lungcancer model by significantly increasing antitumorigenicCD8+cytotoxic T-cell, dendritic cell, and M1 macrophagepopulations through activation of STING and interferonsignaling and induction of expression of PD-L1 andinflammatory chemokines.114Moreover, in an unbiasedlarge-scale siRNA screen, SRA737 is found to be syntheti-cally lethal in combination with subunits of the B-familyof DNA polymerases, POLA1, POLE, and POLE2 inhuman non-small cell lung cancer and colorectal cancercell line”
https://onlinelibrary.wiley.com/doi/pdf/10.1002/aac2.12047
New at ten story on Cine coming up
Gropelad why don’t you go back further than 12 mths and let us know how much we have gained??
We know maths is not your strong subject, not long now before your back behind your school desk, roll on sept.
It’s been a very quite year for news from the BoD so far when you compare it to others, and yet a lot is happening. Our resident snoops have been working overtime to dig out snippets of info. Something must be about to erupt to warrant the £5m + investment that is yet to come to fruition.
Best of luck to everyone
From Sept 2018…..
Dr Tim Mitchell, CEO of Sareum, commented: “TYK2 and JAK1 have emerged in recent years as important targets for new drugs with potential to treat a broad range of autoimmune diseases. This has naturally led to some serious interest from the major pharmaceutical companies, including Pfizer, Bristol-Myers Squibb and Celgene having their own clinical and preclinical programmes in this area. With SDC-1801, we believe we are entering this space with a strong candidate that exhibits potentially best-in-class features. We intend to focus our resources on advancing SDC-1801 through preclinical development and into clinical trials over the next 18 months. At the same time, we will continue our discussions with potential licence partners for this exciting drug candidate.”
Sareum has an ongoing co-development agreement with SRI International (Menlo Park, CA, USA) to develop TYK2 inhibitors in autoimmune diseases. Sareum retains commercialisation rights for these and other TYK2 inhibitors with profiles optimised for oncology indications.
Another Great spot potnak, here the journal report mentioned in the RNS…
https://www.jimmunol.org/content/193/7/3278